Cargando…

Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies

Preeclampsia (PE) is the leading cause of maternal and perinatal morbidity and mortality and also is a risk factor for cardiovascular and kidney disease later in life. PE is associated with oversecretion of autoantibodies against angiotensin II type 1 receptor (AT1-AA) by the placenta into the mater...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhai, Ruonan, Liu, Yuan, Tong, Jiahao, Yu, Ying, Yang, Lin, Gu, Yong, Niu, Jianying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984158/ https://www.ncbi.nlm.nih.gov/pubmed/35401209 http://dx.doi.org/10.3389/fphar.2022.826792

Ejemplares similares

Angiotensin II type 1 receptor agonistic autoantibody blockade improves postpartum hypertension and cardiac mitochondrial function in rat model of preeclampsia
por: Booz, George W., et al.
Publicado: (2021)

The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia
por: Irani, Roxanna A., et al.
Publicado: (2009)

Role of agonistic autoantibodies against type-1 angiotensin II receptor in the pathogenesis of retinopathy in preeclampsia
por: Liu, Fang, et al.
Publicado: (2016)

Angiotensin 1-7 and its analogue decrease blood pressure but aggravate renal damage in preeclamptic mice
por: Liu, Yuan, et al.
Publicado: (2022)

Association of Angiotensin Receptor Autoantibodies With Cardiovascular Abnormalities in Preeclampsia
por: Minhas, Anum S., et al.
Publicado: (2021)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia
por: Liu, Chen, et al.
Publicado: (2015)

Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
por: Luo, Li-Fei, et al.
Publicado: (2021)

Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
por: Ma, Yuting, et al.
Publicado: (2022)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

From Agonist to Antagonist: Modulation of the Physiological Action of Angiotensins by Protein Conjugation—Hemodynamics and Behavior
por: Zamolodchikova, Tatyana S., et al.
Publicado: (2021)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
por: Xue, Genlong, et al.
Publicado: (2022)

Extract of Plantago asiatica L. Seeds Ameliorates Hypertension in Spontaneously Hypertensive Rats by Inhibition of Angiotensin Converting Enzyme
por: Tong, Ren-Chao, et al.
Publicado: (2019)

Angiotensin Type 2 Receptor Gene Polymorphisms and Susceptibility to Preeclampsia
por: Soltani-Zangbar, Mohammad Sadegh, et al.
Publicado: (2018)

Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
por: Ren, Changzhen, et al.
Publicado: (2021)

Cannabinoid receptor agonist attenuates angiotensin II–induced enlargement and mitochondrial dysfunction in rat atrial cardiomyocytes
por: Altieri, Danielle I., et al.
Publicado: (2023)

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review
por: Liu, Jinyu, et al.
Publicado: (2023)

Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer
por: Ren, Boxue, et al.
Publicado: (2019)

Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
por: Qin, Lu-Yun, et al.
Publicado: (2022)

Ginsenoside Rc Ameliorates Endothelial Insulin Resistance via Upregulation of Angiotensin-Converting Enzyme 2
por: Wang, Yaozhen, et al.
Publicado: (2021)

In Vivo Effects of Bradykinin B(2) Receptor Agonists with Varying Susceptibility to Peptidases
por: Jean, Mélissa, et al.
Publicado: (2016)

Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats
por: Zhang, Wei, et al.
Publicado: (2008)

Artemether ameliorates adriamycin induced cardiac atrophy in mice
por: Weng, Wenci, et al.
Publicado: (2023)

Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin
por: Wang, Yingying, et al.
Publicado: (2020)

The Cooperative Effect of Local Angiotensin-II in Liver with Adriamycin Hepatotoxicity on Mitochondria
por: Taskin, Eylem, et al.
Publicado: (2016)

Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats
por: Ashraf, Ghulam Md, et al.
Publicado: (2021)

A Retinoid X Receptor Agonist Directed to the Large Intestine Ameliorates T-Cell-Mediated Colitis in Mice
por: Matsumoto, Ryohtaroh, et al.
Publicado: (2021)

Estrogen-Related Receptor γ Agonist DY131 Ameliorates Lipopolysaccharide-Induced Acute Liver Injury
por: Ma, Haoyang, et al.
Publicado: (2021)

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro
por: Li, Ting, et al.
Publicado: (2021)

Empagliflozin Reduces Renal Hyperfiltration in Response to Uninephrectomy, but Is Not Nephroprotective in UNx/DOCA/Salt Mouse Models
por: Tauber, Philipp, et al.
Publicado: (2021)

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
por: Tang, Yi, et al.
Publicado: (2022)

Stachydrine Ameliorates Cardiac Fibrosis Through Inhibition of Angiotensin II/Transformation Growth Factor β1 Fibrogenic Axis
por: Liu, Xiao, et al.
Publicado: (2019)

Experimental Study on the Mechanism of Cinnamaldehyde Ameliorate Proteinuria Induced by Adriamycin
por: He, Dan, et al.
Publicado: (2022)

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Yi-Shen-Hua-Shi Granule Alleviates Adriamycin-Induced Glomerular Fibrosis by Suppressing the BMP2/Smad Signaling Pathway
por: Tan, Zhuojing, et al.
Publicado: (2022)

Lipoxin A(4) suppresses angiotensin II type 1 receptor autoantibody in preeclampsia via modulating caspase-1
por: Liu, Haojing, et al.
Publicado: (2020)

Association of Angiotensin II Type 1 Receptor Agonistic Autoantibodies With Outcomes in Patients With Acute Aortic Dissection
por: Wu, Xiao-wei, et al.
Publicado: (2021)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct
por: Sinha, Frederick, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n5ekpkmhrjckqctlgtqa2r281t